CN101732413A - Chinese medicinal composition for treating arthromyodynia and preparation method thereof - Google Patents
Chinese medicinal composition for treating arthromyodynia and preparation method thereof Download PDFInfo
- Publication number
- CN101732413A CN101732413A CN200810152968A CN200810152968A CN101732413A CN 101732413 A CN101732413 A CN 101732413A CN 200810152968 A CN200810152968 A CN 200810152968A CN 200810152968 A CN200810152968 A CN 200810152968A CN 101732413 A CN101732413 A CN 101732413A
- Authority
- CN
- China
- Prior art keywords
- semen strychni
- radix
- powder
- modulation
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 118
- 239000000843 powder Substances 0.000 claims abstract description 96
- 229920002472 Starch Polymers 0.000 claims abstract description 30
- 239000008107 starch Substances 0.000 claims abstract description 30
- 235000019698 starch Nutrition 0.000 claims abstract description 30
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001353 Dextrin Polymers 0.000 claims abstract description 20
- 239000004375 Dextrin Substances 0.000 claims abstract description 20
- 235000019425 dextrin Nutrition 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims description 140
- 238000000034 method Methods 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 36
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 claims description 34
- 241000756943 Codonopsis Species 0.000 claims description 33
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 33
- 241000180649 Panax notoginseng Species 0.000 claims description 33
- 241000237636 Pheretima Species 0.000 claims description 33
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 32
- 239000000796 flavoring agent Substances 0.000 claims description 29
- 235000019634 flavors Nutrition 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 27
- 238000011049 filling Methods 0.000 claims description 26
- 238000000498 ball milling Methods 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 21
- 241001279009 Strychnos toxifera Species 0.000 claims description 17
- 229960005453 strychnine Drugs 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 244000107975 Strychnos nux-vomica Species 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 30
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 19
- 210000002437 synoviocyte Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 description 11
- 210000001258 synovial membrane Anatomy 0.000 description 11
- 210000000544 articulatio talocruralis Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001111421 Pannus Species 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011694 lewis rat Methods 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229960000965 nimesulide Drugs 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000005222 synovial tissue Anatomy 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 101100503586 Rattus norvegicus Furin gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000005004 lymphoid follicle Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 241001113846 Loganiaceae Species 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 241001113787 Strychnos Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal composition for treating arthromyodynia and a preparation method thereof. The Chinese medicinal composition is prepared from pilose asiabell root, danshen root, rhizoma atractylodis macrocephalae, earthworm, Indian buead, radix pseudo-ginseng, szechuan lovage rhizome, nux vomica preparation powder, chaff flower root and liquoric root, wherein the nux vomica preparation powder is prepared from the following raw material medicaments: nux vomica and an auxiliary material; and the auxiliary material is selected from one or a mixture of dextrin, starch, mannite, microcrystalline cellulose and calcium bicarbonate. The Chinese medicinal composition for treating the arthromyodynia can reduce the content of the nux vomica in the medicament, thereby reducing the toxic and side effect of the medicament.
Description
Technical field
The present invention relates to field of medicaments, particularly relate to a kind of Chinese medicine composition for the treatment of arthromyodynia and preparation method thereof.
Background technology
The origin of " arthromyodynia " speech will be traced back to China's classic of TCM Huangdi's Internal Classics the earliest, in " element is asked the numbness opinion ", have " wet three gas of wind and cold are assorted extremely, close and be numbness also " say." numbness " person close also, is that obstructed meaning is closed in resistance.The traditional Chinese medical science thinks that arthromyodynia is by exopathogen invasion and attack human bodies such as wind, cold, wet, heat, the impatency meridians, cause QI-blood circulation smooth due to.This disease with muscle, muscles and bones, joint ache, numb, weighing, joint stuffiness, or the scorching hot pain of arthroncus etc. is main clinical manifestation.Ancient times are a lot of to the argumentation of arthromyodynia, as " migratory BI-syndrome caused mainly by pathogenic wind, BI-syndrome caused mainly by pathogenic cold being called painful BI; the dampness victor is a damp arthralgia " etc., also have rheumatism involving the bone, muscular rheumatism, BI-syndrome involved the blood vessels, BI-syndrome involved the muscle, syndromes caused by obstructed QI in five ZANG-organs, arthralgia due to stagnation of blood, severe and migratory arthralgia, gout, general arthralgia or the like, though item are various, its basic pathology then is consistent.The treatment of arthromyodynia is with Xuan Tongwei master, and cooperate according to concrete clinical manifestation dispel the wind, cold expelling, damp eliminating, heat clearing away, invigorate blood circulation, promoting the flow of QI in the collateral by warming the meridian, benefiting QI and nourishing blood etc.Because with the passing of time arthromyodynia normal touching, outbreak repeatedly be difficult to radical cure, and wine has the property of hot Wen Xuantong, can help the power of exempting from all medicines of numbness again, the place of all disease located in tendon in the through meridians blood vessels joint of capacity for liquor priming is so that medicated wine is controlled the numbness curative effect is distinguished, and reside and control in meals, drink-service for a long time enjoys patient and his family's welcome.Therefore, the medicated wine important hands that become arthromyodynia treatment is ruined.It should be noted that the medicine of some treatment arthromyodynias, as the Radix Aconiti Lateralis Preparata of the big heat of Da Xin, Radix Aconiti, Radix Aconiti Kusnezoffii, Semen Strychni etc., owing to have certain toxicity, excessive use easily to cause poisoning, even threat to life, thereby highly necessary careful when using, can not be excessive, so as to avoid an accident.Semen Strychni is the dry mature seed of loganiaceae plant Semen Strychni 8trychnos nux-vomica L. or Yunnan Semen Strychni Strychnos pierriana A.W.Hill.The mature fruit of gathering winter is taken out seed, dries.Its character is the button-type circular plate type, diameter 1.5～3cm, and thick 0.3～0.6cm, normal one side is swelled, and one side is recessed slightly, and the surface is close by greyish brown or celadon thin,tough silk shape fine hair, to arranging radially, a sample gloss is arranged from middle all around.The edge swells slightly, and is thicker, the bossed hole of bead, the bossed round point shape hilum of bottom center.Matter is hard, the visible yellowish white endosperm of parallel section, cutin shape, cotyledon heart, 5～7 of veins.Odorless, flavor are extremely bitter.Semen Strychni nature and flavor hardship, temperature; Very toxic, return liver, spleen channel.It has removing obstruction in the collateral to relieve pain, mass dissipating and swelling eliminating.Be mainly used in rheumatoid arthritis stubborn, paralysis and numbness, injury from falling down, ulcer sore pain; Poliomyelitis sequela, rheumatoid arthritis.Safe, effective, quality controllable is the fundamental of a medicine of overall merit.But because characteristics such as Chinese medicine, natural medicinal ingredients complexity, effective ingredient is clear inadequately, the quality of Chinese medicine preparation often needs to control by each side such as crude drug (comprising medical material, extract or effective ingredient etc.), technology, quality standard, stability.The prescription flavour of a drug should be consistent with primary standard, but at present for some medicine because primary standard situation complexity, some flavour of a drug base is former indeterminate, whether be difficult to estimate the medical material that feeds intake consistent with primary standard, though it is basic former but cannot calibrate standard that the flavour of a drug in some medicine are clear and definite, particularly the medical material if any the special processing specification should feed intake by the requirement of primary standard unanimity when feeding intake in some drug prescriptions, to improve curative effect of medication or to reduce drug toxicity.When containing Semen Strychni Pulveratum or Semen Strychni (modulation) in some drug prescription, should be according to the content range (as FENGTONGNING PIAN) in the strychnine gauge customization agent in the Semen Strychni Pulveratum that feeds intake; More should feed intake strychnine amount in the Semen Strychni (processed) with strychnine content in the control preparation by control, as in the 'Gu Jin Wan ' capsule strychnine amount day clothes maximum should be less than 4.92mg.But for present many medicines that contain Semen Strychni Pulveratum, as with pharmacopeia Semen Strychni Pulveratum (the containing strychnine 0.78-0.82%) preparation prescription that feeds intake medicine, its actual inventory is then different with quality standard.
Summary of the invention
Technical problem to be solved by this invention provides a kind of Chinese medicine composition for the treatment of arthromyodynia.
Another technical problem to be solved of the present invention provides a kind of preparation method for the treatment of the Chinese medicine composition of arthromyodynia.
The present invention treats the Chinese medicine composition of arthromyodynia, be to make: Radix Codonopsis 7.5～30g, Radix Salviae Miltiorrhizae 5～20g, the Rhizoma Atractylodis Macrocephalae 7.5～30g, Pheretima 0.5～5g, Poria 7.5～30g, Radix Notoginseng 5～20g, Rhizoma Chuanxiong 10～40g, Semen Strychni modulation powder 5～25g, Radix Achyranthis Bidentatae 5～20g and Radix Glycyrrhizae 7.5～30g by following materials of weight proportions medicine, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 0.1～5, adjuvant 0.1～5, described adjuvant are selected from one or more mixing in dextrin, starch, mannitol, microcrystalline Cellulose, the calcium bicarbonate.
The Chinese medicine composition of preferred therapeutic arthromyodynia of the present invention, be to make: Radix Codonopsis 10～20g, Radix Salviae Miltiorrhizae 8～15g, the Rhizoma Atractylodis Macrocephalae 10～20g, Pheretima 0.8～3g, Poria 10～20g, Radix Notoginseng 8～15g, Rhizoma Chuanxiong 15～30g, Semen Strychni modulation powder 7.6～15.12g, Radix Achyranthis Bidentatae 8～15g and Radix Glycyrrhizae 10～20g by following materials of weight proportions medicine, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 0.5～2, adjuvant 0.4～2, described adjuvant are selected from one or more mixing in dextrin, starch, mannitol, the microcrystalline Cellulose.
The Chinese medicine composition of the treatment arthromyodynia of the best of the present invention, be to be made by following materials of weight proportions medicine: Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Semen Strychni modulation powder 11.36g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 1, starch 0.5～1.5.
The present invention treats the Chinese medicine composition of arthromyodynia, adopts following method preparation:
A, the Radix Codonopsis of getting weight proportion, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Semen Strychni modulation powder, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are standby;
9 flavors such as b, Radix Codonopsis, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are pulverized, and with Semen Strychni modulation powder mix homogeneously, make preparation.
The present invention treats the Chinese medicine composition of arthromyodynia, is capsule, tablet, granule, pill.
The present invention treats the Chinese medicine composition of arthromyodynia, and wherein said Semen Strychni modulation powder adopts following method preparation:
A. it is standby to get weight proportion crude drug Semen Strychni and appropriate amount of auxiliary materials;
B. adopt single jar and grind the method for converting, Semen Strychni and suitable adjuvant mix homogeneously, during disposable then adding ball milling is irritated, mixed platform 30～90 minutes, the collection gained grinds to convert in the always mixed filling of powder input and mixed 2～4 hours, promptly.
The present invention treats in the Chinese medicine composition of arthromyodynia, and the content of strychnine is 1.10～1.20% in the described Semen Strychni modulation powder.
The present invention treats in the Chinese medicine composition of arthromyodynia, moisture≤9.0% of described Semen Strychni modulation powder.
A kind of preparation method for the treatment of the Chinese medicine composition of arthromyodynia is characterized in that step is as follows:
A. get weight proportion crude drug Semen Strychni 0.1～5, adjuvant 0.1～5; Described adjuvant is selected from one or more mixing in dextrin, starch, mannitol, microcrystalline Cellulose, the calcium bicarbonate; Adopt single jar and grind the method for converting, Semen Strychni and suitable adjuvant mix homogeneously, disposable then adding ball milling mixed 30～90 minutes in irritating, and collected gained and ground and convert the powder input and always mix and mixed 2～4 hours in irritating, and being prepared into Semen Strychni, to modulate powder standby;
9 flavors such as b, the Radix Codonopsis of getting weight proportion, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are pulverized, and with Semen Strychni modulation powder mix homogeneously, make preparation.
The raw material that the present invention treats the Chinese medicine composition of arthromyodynia form and preparation method in crude drug and supplementary product consumption when producing, can increase or reduce according to corresponding ratio, as large-scale production can be unit with the ton, small-scale production can be unit with the gram also, weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
The present invention treats the Chinese medicine composition of arthromyodynia, is mainly used in the treatment insufficiency of vital energy and blood, the resistance of the rheumatism stasis of blood, muscle joint aches, arthroncus, stiffness and deforming or amyotrophy, shortness of breath and fatigue; Rheumatism, rheumatoid arthritis, lumbar muscle strain, soft tissue injury belong to above-mentioned patient.Its medicine composition mainly contains 10 herbal medicines such as Semen Strychni (modulation powder), Pheretima, Radix Codonopsis, Poria, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Achyranthis Bidentatae.Because Semen Strychni wherein has severe toxicity, so pharmacopeia has the control of strictness to the consumption of Semen Strychni.Because Chinese medicine, natural drug have characteristics such as complicated component, effective ingredient be clear inadequately, the quality of Chinese medicine preparation need be controlled by each side such as crude drug (comprising medical material, extract or effective ingredient etc.), technology, quality standard, stability.For medicine of the present invention, according to Semen Strychni provided by the invention modulation powder control feed intake in strychnine amount in the Semen Strychni with strychnine content in the control medicine of the present invention, not only meet and " to the content requirement of strychnine in the Semen Strychni Pulveratum, also can guarantee the curative effect of preparation in the Chinese pharmacopoeia 2005 editions.
Beneficial effect below by medicine of the present invention (obtaining) following pharmacodynamics and pharmacology test explanation medicine of the present invention according to embodiment 18 preparation methoies.
Test of the influence of 1 medicine of the present invention to rheumatoid arthritis (RA) patient t lymphocyte subsets of peripheral blood
1. data and method
1.1 sample source
In two groups of cases of clinical research, 20 couples of patients of picked at random, normal group 20 examples are chosen from the healthy volunteer.
1.2 reagent and instrument
The EPICS XI of U.S. Beckman Coulter Inc. (COULTER) type flow cytometer, IgG-FITC/IgG-PE-Cy5 (catN01672) and CD4-FITC/CD8-PE/CD3-PE-Cy5 (cat N01650) provide by Immunotech Acoulter company.
1.3 experimental technique
1) all persons under inspection are all in aseptic on an empty stomach peripheric venous blood 1ml, the anticoagulant heparin adopted in early morning.
2) get two and go up the sample pipe, identify A, B respectively, and put on this shop simultaneously.
3) get 10 μ l IgG-FITC/IgG-PE-Cy5 and add to the A pipe, 10 μ l CD4-FITC/CD8-PE/CD3-PE-Cy5 add to the B pipe.
4) get 100 μ l anticoagulations respectively and add to A, B two pipes, of short duration immediately whirlpool mixing, 15min (carefully avoid blood sample to add to test tube wall, cause fully mixing of blood sample and reagent) is hatched in the room temperature dark place.
5) add 500 μ l hemolysin O ptiIyse C to A, B two pipes, of short duration immediately whirlpool mixing, 10min is hatched in the room temperature dark place.
6) add 500 μ l PBS solution, of short duration immediately whirlpool mixing stops haemolysis, and machine testing is gone up in 4 ℃ of preservations in the 24h.
1.4 statistical procedures
All The data SPSS13.0 software processes, with
The ANOVA check is adopted in expression.
2 results
The treatment group has been compared significant difference with matched group CD4+, CD8+, CD4+/CD8+ ratio with normal group before the treatment, P＜0.05, and treatment group and matched group CD4+, CD4+/CD8+ ratio significantly raise than normal group, and CD8+ significantly reduces than normal group.Significantly reduce before more all having significant difference P＜0.05, two a group treatment back CD4+ to treat before two groups of CD4+, CD8+, CD4+/CD8+ treatment back and treatments, P＜0.05, CD8+, CD4+/CD8+ ratio significantly reduce P＜0.05 before treating; Treatment back treatment group and matched group be there was no significant difference relatively, and P＞0.05 sees Table II-1.
The comparison of the Table II-1 liang different subgroups of group peripheral blood lymphocyte
Annotate:
★With the treatment before significant difference (P＜0.05) is relatively arranged.
△With normal group significant difference (P＜0.05) is arranged relatively.
3. conclusion
The T cell subsets is to the stable important regulatory role that plays of body's immunity.This result of study shows that RA patient and normal person compare, and peripheral blood CD3+ cell does not have significant change, and the CD4+ cell obviously raises than the normal person, and the CD8+ cell obviously reduces, and CD4+/CD8+ ratio obviously raises, and it is unbalance to exist the T cell subsets.After Drug therapy of the present invention, the CD4+ cell obviously reduces, and the CD8+ cell obviously raises, and CD4+/CD8+ ratio reduces.Clinical observation result shows that these cases enter the catabasis from active stage after treating, the RA state of an illness tends towards stability, the prompting cellular immunization has participated in the pathogenic process of RA, advancing of disease changes with the variation of RA patient's t lymphocyte subsets of peripheral blood closely related, along with the control of the state of an illness, the alleviation of symptom, CD4+, CD8+ cell and CD4+/CD8+ ratio are tending towards normal.
Test the 2 former inductivity arthritis of medicine anticol of the present invention (CIA) effect research
1 materials and methods
1.1 material
1.1.1 animal
60 of cleaning level Lewis rats, male, body weight (180 ± 10) g, available from Beijing Vital River Experimental Animals Technology Co., Ltd., the animal quality certification number: 2002-0003; Feeding environment: The First Affiliated Hospital of Tianjin University of Traditional Chinese Medic's cleaning level Animal House.Adaptability is used for experiment after raising for 1 week.
1.1.2 reagent
(Complete Freund ' s Adjuvant is CFA) all available from U.S. Sigma company for cattle II Collagen Type VI (Collagen Type II, C II) and Freund's complete adjuvant;
Osmic acid: JOHNSON MATTHEY CHEMICALS LTD. product, ENGLAND;
Nimesulide: JIANLIBAO pharmaceutcal corporation, Ltd in Guangdong produces (lot number: 050402)
Medicine of the present invention, Tianjin DaRenTang DaEr Medicine Co., Ltd produces (lot number: 301414).
1.1.3 key instrument
Microtome, Leica Jung Biocut 2035, Germany;
Agitator, Tai County, Jiangsu Province medical apparatus and instruments factory;
The desk type high speed refrigerated centrifuger, Fourth Ring, Beijing scientific instrument factory;
Optical microscope, OIYMPUS BX51, Japan.
Electronic Speculum, (OTONEMIOC, Germany)
1.2 method
1.2.1 Emulsion preparation
C II is dissolved in the 0.1M glacial acetic acid, and concentration is 2mg/ml, stirs down at 4 ℃ and makes it abundant dissolving, places 4 ℃ of refrigerator overnight.
1.2.2 model preparation
Random choose is 10 in 60 Lewis rats, and as normal group, all the other 50 in order to the CIA modeling.The modeling concrete steps are as follows: the C II that is dissolved in glacial acetic acid adds isopyknic CFA, and mixing under condition of ice bath makes the two fully emulsified (with indiffusion degree of being in the emulsion droplet entry), and the CII ultimate density is 1mg/ml.In the right sufficient subcutaneous injection CII collagen Emulsion of rat, every rat 0.2ml.Booster immunization behind the initial immunity 21d is at the subcutaneous injection 0.2ml of Mus root of the tail portion Emulsion.The general situation of routine observation rat, variations such as extremities joint swelling, color, joint motion situation.
1.2.3 the swell-foot expansibility is measured
Cause scorching before and behind the initial immunity 1d rise, every 2d survey 1 metapedes anteroposterior diameter, about footpath and sufficient mat thickness, with this as observation index.
1.2.4 arthritis scoring
21d behind the initial immunity adopts the generation and the order of severity of joint mark point system record polyarthritis pathological changes, and (Arthritis index AI) is divided into 5 grades (0-4 branches), 0 minute to arthritis index: do not have red and swollen; 1 minute: sufficient little toe joint was red and swollen; 2 minutes: toe joint, sufficient sole of the foot portion were all red and swollen; 3 minutes: ankle joint was following all red and swollen; 4 minutes: comprise ankle joint, all red and swollen; Be up to 16 fens, every record scoring in 2 days 1 time.
1.2.5 grouping and administration
45 of causing in the scorching rat of 50 CII the Secondary cases arthritic symptom occurs in immunity in succession, and rubescent swelling appears in extremity (particularly two hind leg), and arthritis index 〉=6 are divided into the modeling success.36 Lewis rats of CIA modeling success are divided into medicine high dose group of the present invention, medicine low dose group of the present invention, nimesulide group, model group at random, every group of 9 rats.And 10 rats of random choose before the modeling are made normal group.
Lewis rat CII causes scorching back the 21st day, begins to irritate stomach.
Medicine high dose group of the present invention, the water-soluble filling stomach of medicine of the present invention, 1.8g/kg.d (be equivalent to normal adult consumption 35 times);
Medicine low dose group of the present invention, the water-soluble filling stomach of medicine of the present invention, 0.36g/kg.d (be equivalent to normal adult consumption 7 times);
Nimesulide group: water-soluble filling stomach 6mg/kg.d;
Model group, normal saline is irritated stomach, 10ml/kg.d;
Administration continues 6W.
1.2.6 pathological observation
Administration 6W, put to death rat after the 3% pentobarbital sodium intraperitoneal anesthesia, peel off to cut and respectively organize left ankle joint tissue, put into 10% neutral formalin solution immediately, fixedly behind the 2d, 8% formic acid decalcification 14d, conventional gradient ethanol dehydration, paraffin embedding, section, conventional H E dyeing, microscopically is observed joint and synovial membrane pathological change.
1.2.7 the Ultrastructural observation of synovial cell
Get rat knee joint synovial tissue, pre-fix with 4% glutaraldehyde Milloning ' s buffer, 1% osmic acid fixative is fixed, different concentration ethanol is dewatered step by step, the expoxy propane transition, Epon 812 soaks, embedding, back, location row ultrathin section, after the two dyeing of acetic acid uranium and lead citrate, transmission electron microscope observing synovial cell ultrastructure is also taken the photograph sheet.
1.3 statistical procedures
Above experimental data is used the SPSS13.0 statistical software and is handled, the data statistics result with
The ANOVA check is carried out in expression.
2 results
2.1CIA rat model prepares situation
2.1.1 the incidence of CIA
Initial immunity next day, rat immunity side ankle joint skin begins rubescent, swelling.Cause scorching back 10-19d, rat extremities joint redness increases the weight of, and is obvious with bilateral metapedes ankle joint, and the foot pad thickens, and the activities in rats amount reduces, and appetite descends, and hair tarnishes, and the many places aphtha appears in the intradermal injection position, incrustation healing subsequently.5W left and right sides rat arthritis pathological changes is the most serious, movable difficulty, and body weight gain is slow, even descends.Thereafter arthroncus is faded, and ankylosis appears in the part rat, and activity is obviously limited.
2.1.2 CIA rat joint pathology changes
The pathological section HE demonstration of dyeing: the synovial tissue of joint of normal group is made up of 1-2 layer synovial cell and synovial membrane lower floor, and synovial cell's marshalling is flat, and articular surface is smooth, does not have in the articular cavity and oozes out no cell infiltration.The synovial tissue of model group obviously thickens, and severe patient reaches 10 multilamellars, arranges evacuation, disorder, and synovial villi forms prominent to articular cavity; Synovial membrane lower floor visible many places kitchen range lymphocytic infiltration, plasma cell that is dispersed in and macrophage, form " lymphoid follicle ", newborn little blood vessel quantity increases under the synovial membrane, the blood vessel endothelium hypertrophy, luminal stenosis even obturation, pannus forms, synovial tissue occurs and attach the cartilage-derived growth phenomenon, cartilage corrodes, destroys.
2.2 medicine is to the influence of CIA rat performance
2.2.1 influence to the general incidence of CIA rat
Normal rats fur color gloss is white, and spirit is good, active, and diet is normal; The intensely dark pool of model group rat fur, part rat creep difficulty, the decreased food intake of receiving is few, the bodily form is thin and weak; The withered rough jaundice of medicine low dose group rat fur of the present invention, asthenia is lazy moving, and body weight gain is slow; Medicine high dose group of the present invention and nimesulide group rat fur gloss, active, the feed situation is better.
2.2.2 influence to CIA rat Secondary cases pathological changes
2.2.2.1 11d behind the initial immunity observes minority rat (6/40) and begins to occur insecondary ankle redness, to 19d, Secondary cases arthritis in various degree all takes place in the modeling rat of most of (36/40).
2.2.2.2 the ankle swelling after the Drug therapy changes situation
Medicine low dose group metapedes swollen ankles degree of the present invention and model group comparing difference have significance behind the filling stomach 6W, P＜0.05, and other each group has significance, P＜0.01 with the model group comparing difference.Medicine low dose group of the present invention and medicine high dose group comparing difference of the present invention have significance, P＜0.05; Medicine low dose group of the present invention and nimesulide group comparing difference have significance, P＜0.01.Medicine high dose group of the present invention and nimesulide group compare, and difference has significance, P＜0.05.Each organizes the inflammation index comparative result: medicine low dose group of the present invention and model group comparing difference have significance, P＜0.05, and other each group has significance, P＜0.01 with the model group comparing difference.Auspicious high dose group of numbness and nimesulide group compare, and difference does not have significance, P＞0.05.
2.2.2.3 influence to CIA rat tissue pathological change
Ankle joint pathology shows: light microscopic is observed model group rat and normal rats relatively down; synovial membrane height hypertrophy appears in the pathological changes ankle joint; be papillae; the cell irregular arrangement; visible a large amount of inflammatory cell infiltration, " lymphoid follicles " structure, cartilage surface destroy, serious even visible inflammatory cell corrodes cartilage, osseous tissue, and has pannus to form.
Nimesulide group ankle joint synovial membrane is normal, and 1～2 layer of synovial cell is regularly arranged, does not see that cell infiltration and pannus form.The visible local slight hypertrophy (3～5 layers of synovial cells) of medicine high dose group synovial membrane of the present invention, the visible slight cell infiltration of part is not also observed pannus.The visible synovial hyperplasia of medicine low dose group of the present invention, the visible new vessels of synovial membrane lining lower floor generates, and cell infiltration is obvious.The ankle joint pathology of medicine high dose group of the present invention and nimesulide group shows that articular cartilage surface is smooth, does not see that cartilage corrodes and subchondral bone destroys, and pathological manifestations is basic consistent with normal rat.Medicine low dose group of the present invention is similar to CIA model group rat ankle joint pathological change.
2.2.2.4 to the Ultrastructural influence of CIA rat synovial cell
Transmission electron microscope observing shows: normal group: the synovial cell is many with type B cell, and wherein rough endoplasmic reticulum is more, and Golgi body and vesicle are rare; Type A cell then has significant Golgi complex and vesicle, the visible slight volume of Golgi body is bent, rough endoplasmic reticulum is rarely found. and model group: type A cell significantly increases among the synovial cell, visible more DB in the synovial cell, Golgi body significantly increases in the synovial cell, as seen serious volume is bent, a large amount of cavitys is arranged, and mitochondrion significantly increases, visible swelling, rough endoplasmic reticulum significantly increases, and expansion being arranged more. medicine high dose group of the present invention and nimesulide group: the synovial cell is all based on type B cell, and Golgi body obviously reduces than model group in the synovial cell, and visible slight volume is bent, mitochondrion and vesicle reduce, and rough endoplasmic reticulum significantly reduces; A type synovial cell Golgi body reduces, and structure is comparatively clear, complete, visible slight curling, and mitochondrion is less, and swelling is not obvious. and medicine low dose group of the present invention: the synovial cell is based on type B cell, and Golgi body reduces than model in the synovial cell, and visible volume is bent; Mitochondrion and vesicle have minimizing slightly, and rough endoplasmic reticulum reduces; A type synovial cell Golgi body reduces, and structure is comparatively clear, complete, and mitochondrion reduces to some extent than model group, visible swelling.
Test of the influence of 3 medicines of the present invention to CIA rat blood serum TNF-α, IL-1 β
1. materials and methods
1.1 reagent
20050705), TNF-α ELISA test kit (lot number: 20050705), be Shenzhen brilliant U.S. company IL-1 β ELISA test kit (lot number:.
1.2 animal modeling and grouping administration: with experiment 2
1.3 the mensuration of cytokine
The mensuration of IL-1 β, TNF-α adopts the ELISA test kit, and detects by the test kit explanation.
1.4 statistical analysis
Data are used the SPSS13.0 statistical software and are handled, the data statistics result with
The ANOVA check is carried out in expression.
2. result
Model group and each treatment group and normal group compare, and IL-1 β expression all raises, and difference all has significance, P＜0.01; Each treatment group and model group compare, and IL-1 β expression all descends, and wherein the decline of nimesulide group and Chinese medicine high dose group is more obvious, and difference has significance, P＜0.01.Model group and each treatment group and normal group compare, and TNF-alpha expression level all raises, and difference all has significance, P＜0.01; Each treatment group and model group relatively all being the variation that descends, and wherein the decline of nimesulide group and Chinese medicine high dose group is more obvious, and difference has significance, P＜0.0l.See Table III-1
Table III-1 medicine of the present invention is to the influence of rat blood serum IL-1 β, TNF-α
Annotate: with normal group significant difference is arranged relatively,
★P＜0.05,
★ ★P＜0.01;
With model group significant difference is arranged relatively,
*P＜0.05,
*P＜0.01.
3. conclusion
RA peripheral blood of patients mononuclear cell and synovium of joint cell are secreted IL-1 β and TNF-α in a large number, and these two kinds of cytokines play a leading role in the disease progressions such as acute synovial membrane inflammation, synovial membrane fibrosis, bone and cartilage destruction of RA.This result of study shows that medicine of the present invention can obviously reduce serum il-1 β, TNF-alpha levels, ameliorate osteoarthritis disease, and may suppress synovial hyperplasia, but must further studies confirm that.
Test 4 medicine experiment of analgesic of the present invention researchs
1. materials and methods
1.1 material
1.1.1 laboratory animal: healthy ICR mice, body weight (20 ± 2) g.The healthy SD rat, male, body weight (200 ± 20) g.
Above animal is II level cleaning level, is provided by Beijing Military Medical Science Institute laboratory center.
1.2. experimental technique
1.2.1 influence to mice hot plate pain
In the trial test ICR mice put on the metal hot plate that is preheated to (55 ± 0.5) ℃, to lick metapedes as the pain indicator reaction, the time that metapedes appears licking in the record mice is as the incubation period (pain threshold) of pain reaction.Choose the mice of pain threshold between 5-30s and be divided into 3 groups at random: 1. matched group (normal saline, 2ml/d); The nimesulide group (the nimesulide capsule, 50mg/kg/d); 3. medicine group of the present invention (medicine of the present invention, 0.6g/kg/d), 10 every group, every day gastric infusion once, continuously 3d. after administration in the 3rd day 30,60,90min respectively measures the pain threshold of a mice.Scald for anti-mice foot, test and be made as 60s deadline.
1.2.2 the influence of the inductive mouse writhing reaction of Dichlorodiphenyl Acetate
The ICR mice is divided into 3 groups at random: 1. matched group (normal saline, 10ml/kg); The nimesulide group (the nimesulide capsule, 40mg/kg/d); 3. medicine group of the present invention (medicine of the present invention, 0.48g/kg/d), 10 every group, every day gastric infusion once, continuous 3d..After last was irritated stomach 30min, mouse peritoneal was injected 0.6% glacial acetic acid solution 0.2ml, in the record 20min mice turn round the body number of times, and calculate the suppression ratio of writhing response.
1.3 statistical analysis
Data are used the SPSS13.0 statistical software and are handled, the data statistics result with
The t check is carried out in expression.
2. result
2.1 medicine of the present invention is to the influence of mice hot plate pain
The result shows that 0.5h behind the drug administration of the present invention can improve the threshold value of hot plate induced mice pain, reaches ceiling effect after one hour, then weakens gradually, and the nimesulide effective time is early than medicine group of the present invention; The pain threshold and the normal saline group of medicine group of the present invention and nimesulide group more all have significant difference, P＜0.05; Medicine group of the present invention and nimesulide group be there was no significant difference relatively, P＞0.05.See Table III-2
Table III-2 medicine of the present invention is to the influence of mice hot plate method pain threshold
Annotate:
*Compare P＜0.05 with the normal saline group.
2.2 the influence of the inductive mouse writhing reaction of medicine Dichlorodiphenyl Acetate of the present invention
The result shows, can obviously reduce the number of times of the mouse writhing reaction due to the cruel acid behind the drug administration of the present invention, with normal saline group comparing difference significance (P＜0.01) arranged, and do not have significance (P＞0.05) with aspirin group comparing difference, sees Table III-3.
The influence of the inductive mouse writhing reaction of Table III-3 medicine Dichlorodiphenyl Acetate of the present invention
Annotate:
*Compare with the normal saline group, P＜0.05,
*Compare P＜0.01 with the normal saline group.
3. conclusion
Last experimental result shows that medicine of the present invention can improve the threshold value of hot plate induced mice pain, and reaches ceiling effect after one hour.In addition, medicine of the present invention also can obviously reduce the number of times of the mouse writhing reaction due to the acetic acid, has good analgesic activity,
Also (lot number: 301483) content of middle strychnine has carried out the contrast experiment, and it meets " 2005 editions regulations to the content of contained strychnine in the medicine of Chinese pharmacopoeia to the Biqi capsules of medicine of the present invention (obtaining according to embodiment 18 preparation methoies) and commercial acquisition in the present invention.
1, according to " 2005 editions Biqi capsules that the regulation of Semen Strychni is produced of Chinese pharmacopoeia
| ??1 | ??2 | ??3 | ??4 | ??5 | |
| The content of strychnine in the Semen Strychni Pulveratum | ??0.78％ | ??0.79％ | ??0.80％ | ??0.81％ | ??0.82％ |
| ??1 | ??2 | ??3 | ??4 | ??5 | |
| The content of strychnine in the Biqi capsules | 0.17mg/ grain | 0.18mg/ grain | 0.19mg/ grain | 0.19mg/ grain | 0.20mg/ grain |
2, the pharmaceutical composition of producing according to the Semen Strychni modulation powder of the inventive method preparation of the present invention
| ??1 | ??2 | ??3 | ??4 | ??5 | |
| The content of strychnine in the Semen Strychni modulation powder | ??1.15％ | ??1.20％ | ??1.15％ | ??1.20％ | ??1.10％ |
| The content of strychnine in the pharmaceutical composition of the present invention | 0.26mg/ grain | 0.27mg/ grain | 0.30mg/ grain | 0.23mg/ grain | 0.22mg/ grain |
Show by above-mentioned experiment, meet the drug quality regulation by the content of strychnine in the pharmaceutical composition of the present invention.
The specific embodiment
Further set forth the preparation method of medicine of the present invention by the following examples.
Embodiment 1
A. get Semen Strychni 0.1kg, dextrin 0.1kg; Adopt single jar and grind the method for converting, Semen Strychni and dextrin mix homogeneously, disposable then adding ball milling mixed 30 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
9 flavors such as b, the Radix Codonopsis 7.5g that gets weight proportion, Radix Salviae Miltiorrhizae 5g, Rhizoma Atractylodis Macrocephalae 7.5g, Pheretima 0.5g, Poria 7.5g, Radix Notoginseng 5g, Rhizoma Chuanxiong 10g, Radix Achyranthis Bidentatae 5g and Radix Glycyrrhizae 7.5g are pulverized, and with Semen Strychni modulation powder 5～25g mix homogeneously of method for preparing, make tablet.
Embodiment 2
A. get Semen Strychni 5kg, dextrin 5kg; Adopt single jar and grind the method for converting, Semen Strychni and dextrin mix homogeneously, disposable then adding ball milling mixed 90 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 4 hours, and it is standby to be prepared into Semen Strychni modulation powder;
9 flavors such as b, the Radix Codonopsis 30g that gets weight proportion, Radix Salviae Miltiorrhizae 20g, Rhizoma Atractylodis Macrocephalae 30g, Pheretima 5g, Poria 30g, Radix Notoginseng 20g, Rhizoma Chuanxiong 40g, Radix Achyranthis Bidentatae 20g and Radix Glycyrrhizae 30g are pulverized, and with the Semen Strychni modulation powder 25g mix homogeneously of method for preparing, make capsule.
Embodiment 3
A. get Semen Strychni 1.5kg, dextrin 2.5kg; Adopt single jar and grind the method for converting, Semen Strychni and dextrin mix homogeneously, disposable then adding ball milling mixed 60 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3 hours, and it is standby to be prepared into Semen Strychni modulation powder;
9 flavors such as b, the Radix Codonopsis 30g that gets weight proportion, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 2g, Poria 20g, Radix Notoginseng 15g, Rhizoma Chuanxiong 30g, Radix Achyranthis Bidentatae 15g and Radix Glycyrrhizae 20g are pulverized, and with the Semen Strychni modulation powder 11g mix homogeneously of method for preparing, make pill.
Embodiment 4
A. get Semen Strychni 0.1kg, starch 5kg; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 30 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 4 hours, and it is standby to be prepared into Semen Strychni modulation powder;
9 flavors such as b, the Radix Codonopsis 15g that gets weight proportion, Radix Salviae Miltiorrhizae 8g, Rhizoma Atractylodis Macrocephalae 25g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 15g, Radix Achyranthis Bidentatae 12g and Radix Glycyrrhizae 25g are pulverized, and with the Semen Strychni modulation powder 8g mix homogeneously of method for preparing, make capsule.
Embodiment 5
A. get Semen Strychni 0.2kg, starch 0.1kg; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 40 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 4 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 10g, Radix Salviae Miltiorrhizae 8g, Rhizoma Atractylodis Macrocephalae 10g, Pheretima 0.8g, Poria 10g, Radix Notoginseng 8g, Rhizoma Chuanxiong 15g, Radix Achyranthis Bidentatae 8g and Radix Glycyrrhizae 10g are pulverized, and with the Semen Strychni modulation powder 7.6g mix homogeneously of method for preparing, make capsule.
Embodiment 6
A. get Semen Strychni 0.5kg, starch 5kg; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 40 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 20g, Radix Salviae Miltiorrhizae 15g, Rhizoma Atractylodis Macrocephalae 20g, Pheretima 3g, Poria 20g, Radix Notoginseng 15g, Rhizoma Chuanxiong 30g, Radix Achyranthis Bidentatae 15g and Radix Glycyrrhizae 20g are pulverized, and with the Semen Strychni modulation powder 15.12g mix homogeneously of method for preparing, make capsule.
Embodiment 7
A. get Semen Strychni 5kg, starch 4kg; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 35 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2.5 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 12g, Radix Salviae Miltiorrhizae 15g, Rhizoma Atractylodis Macrocephalae 10g, Pheretima 3g, Poria 10g, Radix Notoginseng 15g, Rhizoma Chuanxiong 30g, Radix Achyranthis Bidentatae 8g and Radix Glycyrrhizae 20g are pulverized, and with the Semen Strychni modulation powder 10g mix homogeneously of method for preparing, make capsule.
Embodiment 8
A. get Semen Strychni 1kg; Each 0.25kg is standby for dextrin, starch, mannitol, microcrystalline Cellulose and calcium bicarbonate; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 60 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 12g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 12g, Pheretima 2.5g, Poria 12.5g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 9g and Radix Glycyrrhizae 10g are pulverized, and with the Semen Strychni modulation powder 8g mix homogeneously of method for preparing, make capsule.
Embodiment 9
A. it is standby to get each 0.45kg of Semen Strychni 0.6kg, starch, mannitol and microcrystalline Cellulose; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 50 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3.5 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 2g, Poria 12g, Radix Notoginseng 10g, Rhizoma Chuanxiong 30g, Radix Achyranthis Bidentatae 15g and Radix Glycyrrhizae 10g are pulverized, and with the Semen Strychni modulation powder 9g mix homogeneously of method for preparing, make the film agent.
Embodiment 10
A. get Semen Strychni 1kg, mannitol 0.8kg, microcrystalline Cellulose 0.6kg is standby; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 45 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 12g, Radix Salviae Miltiorrhizae 12g, Rhizoma Atractylodis Macrocephalae 12g, Pheretima 1.5g, Poria 12g, Radix Notoginseng 12g, Rhizoma Chuanxiong 12g, Radix Achyranthis Bidentatae 12g and Radix Glycyrrhizae 12g are pulverized, and with the Semen Strychni modulation powder 7g mix homogeneously of method for preparing, make capsule.
Embodiment 11
A. get Semen Strychni 0.2kg, dextrin 0.2kg; Adopt single jar and grind the method for converting, Semen Strychni and dextrin mix homogeneously, disposable then adding ball milling mixed 45 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 20g, Radix Salviae Miltiorrhizae 15g, Rhizoma Atractylodis Macrocephalae 10g, Pheretima 0.8g, Poria 20g, Radix Notoginseng 15g, Rhizoma Chuanxiong 15g, Radix Achyranthis Bidentatae 8g and Radix Glycyrrhizae 20g are pulverized, and with the Semen Strychni modulation powder 7.6g mix homogeneously of method for preparing, make capsule.
Embodiment 12
A. get Semen Strychni 0.4kg, dextrin 0.1kg, calcium bicarbonate 0.5kg is standby; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 70 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3.5 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make capsule.
Embodiment 13
A. get Semen Strychni 2kg, starch 3kg, the standby employing of calcium bicarbonate 2kg is ground the method for converting for single jar, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 80 minutes in irritating, the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make tablet.
Embodiment 14
A. get Semen Strychni 3kg, each 2kg is standby for dextrin and starch; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 55 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 4 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make pill.
Embodiment 15
A. get Semen Strychni 0.5kg, dextrin, starch, each 0.4kg is standby for microcrystalline Cellulose; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 75 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make granule.
Embodiment 16
A. get Semen Strychni 0.2kg, dextrin, each 0.8kg is standby for starch; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 85 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2.5 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make granule.
Embodiment 17
A. get Semen Strychni 0.5kg, starch, each 0.3kg is standby for microcrystalline Cellulose; Adopt single jar and grind the method for converting, Semen Strychni and above-mentioned adjuvant mix homogeneously, disposable then adding ball milling mixed 60 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make capsule.
Embodiment 18
A. get Semen Strychni 1kg, starch 0.5kg is standby; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 60 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 11.36g mix homogeneously of method for preparing, make capsule.
Embodiment 19
A. get Semen Strychni 1kg, starch 1.5kg is standby; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 90 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 4 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 10.56g mix homogeneously of method for preparing, make capsule.
Embodiment 20
A. get Semen Strychni 1kg, starch 1kg is standby; Adopt single jar and grind the method for converting, Semen Strychni and starch mix homogeneously, disposable then adding ball milling mixed 75 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 3 hours, and it is standby to be prepared into Semen Strychni modulation powder;
B. 9 flavors such as Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g are pulverized, and with the Semen Strychni modulation powder 15.12g mix homogeneously of method for preparing, make capsule.
Claims (9)
1. Chinese medicine composition for the treatment of arthromyodynia, its feature is made by following materials of weight proportions medicine: Radix Codonopsis 7.5～30g, Radix Salviae Miltiorrhizae 5～20g, the Rhizoma Atractylodis Macrocephalae 7.5～30g, Pheretima 0.5～5g, Poria 7.5～30g, Radix Notoginseng 5～20g, Rhizoma Chuanxiong 10～40g, Semen Strychni modulation powder 5～25g, Radix Achyranthis Bidentatae 5～20g and Radix Glycyrrhizae 7.5～30g, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 0.1～5, adjuvant 0.1～5, described adjuvant are selected from one or more mixing in dextrin, starch, mannitol, microcrystalline Cellulose, the calcium bicarbonate.
2. the Chinese medicine composition of the described treatment arthromyodynia of claim 1, its feature is made by following materials of weight proportions medicine: Radix Codonopsis 10～20g, Radix Salviae Miltiorrhizae 8～15g, the Rhizoma Atractylodis Macrocephalae 10～20g, Pheretima 0.8～3g, Poria 10～20g, Radix Notoginseng 8～15g, Rhizoma Chuanxiong 15～30g, Semen Strychni modulation powder 7.6～15.12g, Radix Achyranthis Bidentatae 8～15g and Radix Glycyrrhizae 10～20g, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 0.5～2, adjuvant 0.4～2, described adjuvant are selected from one or more mixing in dextrin, starch, mannitol, the microcrystalline Cellulose.
3. the Chinese medicine composition of the described treatment arthromyodynia of claim 2, its feature is made by following materials of weight proportions medicine:, Radix Codonopsis 15g, Radix Salviae Miltiorrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Pheretima 1g, Poria 15g, Radix Notoginseng 10g, Rhizoma Chuanxiong 20g, Semen Strychni modulation powder 11.36g, Radix Achyranthis Bidentatae 10g and Radix Glycyrrhizae 15g, Semen Strychni modulation powder wherein is to be made by following weight proportion crude drug: Semen Strychni 1, starch 0.5～1.5.
4. the Chinese medicine composition of the arbitrary described treatment arthromyodynia of claim 1～3 is characterized in that adopting following method preparation:
A, the Radix Codonopsis of getting weight proportion, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Semen Strychni modulation powder, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are standby;
9 flavors such as b, Radix Codonopsis, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are pulverized, and with Semen Strychni modulation powder mix homogeneously, make preparation.
5. the Chinese medicine composition of the described treatment arthromyodynia of claim 4 is characterized in that said preparation is capsule, tablet, granule, pill.
6. the Chinese medicine composition of the arbitrary described treatment arthromyodynia of claim 1～3 is characterized in that described Semen Strychni modulation powder adopts following method preparation:
A. it is standby to get weight proportion crude drug Semen Strychni and appropriate amount of auxiliary materials;
B. adopt single jar and grind the method for converting, Semen Strychni and suitable adjuvant mix homogeneously, disposable then adding ball milling mixed 30～90 minutes in irritating, and the collection gained grinds to convert in the always mixed filling of powder input and mixed 2～4 hours, promptly.
7. the Chinese medicine composition of the described treatment arthromyodynia of claim 6 is characterized in that, the content of strychnine is 1.10～1.20% in the described Semen Strychni modulation powder.
8. the Chinese medicine composition of the described treatment arthromyodynia of claim 6 is characterized in that, moisture≤9.0% of described Semen Strychni modulation powder.
9. the preparation method of the Chinese medicine composition of the arbitrary described treatment arthromyodynia of claim 1～3 is characterized in that step is as follows:
A. get weight proportion crude drug Semen Strychni 0.1～5, adjuvant 0.1～5; Described adjuvant is selected from one or more mixing in dextrin, starch, mannitol, microcrystalline Cellulose, the calcium bicarbonate; Adopt single jar and grind the method for converting, Semen Strychni and suitable adjuvant mix homogeneously, disposable then adding ball milling mixed 30～90 minutes in irritating, and collected gained and ground and convert the powder input and always mix and mixed 2～4 hours in irritating, and being prepared into Semen Strychni, to modulate powder standby;
9 flavors such as b, the Radix Codonopsis of getting weight proportion, Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, Pheretima, Poria, Radix Notoginseng, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae and Radix Glycyrrhizae are pulverized, and with Semen Strychni modulation powder mix homogeneously, make preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810152968A CN101732413B (en) | 2008-11-13 | 2008-11-13 | Chinese medicinal composition for treating arthromyodynia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810152968A CN101732413B (en) | 2008-11-13 | 2008-11-13 | Chinese medicinal composition for treating arthromyodynia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101732413A true CN101732413A (en) | 2010-06-16 |
| CN101732413B CN101732413B (en) | 2012-08-29 |
Family
ID=42456781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810152968A Active CN101732413B (en) | 2008-11-13 | 2008-11-13 | Chinese medicinal composition for treating arthromyodynia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732413B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285124A (en) * | 2012-02-28 | 2013-09-11 | 刘运来 | Fructus aurantii-nux vomica pill for rheumatism |
| CN103394055A (en) * | 2013-07-19 | 2013-11-20 | 苏州市天灵中药饮片有限公司 | Traditional Chinese medicine containing nux vomica powder and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1522730A (en) * | 2003-02-18 | 2004-08-25 | 毛友昌 | Rheumathritis capsule preparation method |
| CN100353957C (en) * | 2003-07-21 | 2007-12-12 | 天津达仁堂达二药业有限公司 | Chinese medicinal herb composition for treating rheumatism |
-
2008
- 2008-11-13 CN CN200810152968A patent/CN101732413B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285124A (en) * | 2012-02-28 | 2013-09-11 | 刘运来 | Fructus aurantii-nux vomica pill for rheumatism |
| CN103394055A (en) * | 2013-07-19 | 2013-11-20 | 苏州市天灵中药饮片有限公司 | Traditional Chinese medicine containing nux vomica powder and preparation method thereof |
| CN103394055B (en) * | 2013-07-19 | 2014-12-17 | 苏州市天灵中药饮片有限公司 | Traditional Chinese medicine containing nux vomica powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101732413B (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104689226A (en) | Traditional Chinese medicine composition for treating children with rheumatoid arthritis and preparation method thereof | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN103405582B (en) | Traditional Chinese medicine composition for improving joint gall of rheumatoid arthritis | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101780146B (en) | Quality control method of Biqi capsules | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN101732413B (en) | Chinese medicinal composition for treating arthromyodynia and preparation method thereof | |
| CN103285206B (en) | Traditional Chinese medicinal liquor for treating rheumatic arthritis | |
| CN1507884A (en) | Chinese medicine powder and decoction composition for treating cancers | |
| CN101979013B (en) | Traditional Chinese medicine for treating leukemia | |
| CN104706839A (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis | |
| CN104784508B (en) | For improving the preparation method of the Chinese medicine preparation of malignant tumor patient immunologic function | |
| CN104825817A (en) | Traditional Chinese medicine preparation with antitumor effect | |
| CN104605051A (en) | Double hemp-folium cortex eucommiae tea and preparing method thereof | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN104784509B (en) | For improving the Chinese medicine preparation of malignant tumor patient immunologic function | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN109381662A (en) | The Chinese medicine composition and its preparation method and application for treating prostate cancer | |
| CN106361829A (en) | Traditional Chinese medicine composition for treating ischemic stroke, preparation and preparation method thereof | |
| CN107737259A (en) | A kind of Chinese prescription for improving male's sexual | |
| CN110123871B (en) | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof | |
| CN101884756A (en) | Pharmaceutical composition with functions of expelling wind and removing dampness and activating collaterals and relieving pain, preparation method, preparation and application thereof | |
| CN104645079A (en) | Traditional Chinese medicine for treating post-stroke limb numbness | |
| CN105213721A (en) | A kind of Chinese medicine preparation for the treatment of gastroptosis | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 300112 No. 20 Daming Road, Xiqing District, Tianjin Patentee after: Jinyao Darrentang Jingwanhong (Tianjin) Pharmaceutical Co.,Ltd. Country or region after: China Address before: 300112 No. 20 Daming Road, Xiqing District, Tianjin Patentee before: TIANJIN DARENTANG JINGWANHONG PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |